FDAnews
www.fdanews.com/articles/146284-savient-rsquo-s-loss-widens-shares-fall

Savient’s Loss Widens, Shares Fall

May 9, 2012
Savient Pharmaceuticals posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent. The drugmaker, which is under pressure from its largest creditor to liquidate itself, said it expects sales of branded and generic versions of its other drug oxandrolone — used to promote weight gain following involuntary weight loss — to decline through the year.
Sun Sentinel